Notably, treatment of lung cancer cells with the EGFR tyrosine kinase inhibitor, gefitinib, or the KRAS-G12C inhibitor, AMG 510, reduced CD47 expression, which is consistent with the newly discovered mechanisms of CD47 regulation by EGFR and KRAS [110,164,222]. This evidence concerns the gene KRAS and lung carcinoma.